{ "docId": "019dd923-622c-750b-8b99-bca3fd68622d", "docSlug": "4c8fe6013c68", "documentTitle": "iRhythm Technologies, Inc. (IRTC)", "authorId": "54_Spruce_Point_Capital", "authorName": "Spruce Point Capital Management", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-18 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 17, "pageCount": 101, "prevPage": 16, "nextPage": 18, "slideType": "expose_contradiction", "function": "expose_contradiction", "density": "overcrowded", "nDataPoints": 0, "notes": "Uses a 'not equal' symbol to visually represent the contradiction between management's pitch and reality.", "elementsJson": [ "headline_text", "callout_box", "comparison_table", "paragraph", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b99-bca3fd68622d/17", "deckHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d", "deckJsonHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-bca3fd68622d#slide-17", "components": [ { "bbox": null, "kind": "callout", "text": "The Zio AT has long been promoted by iRhythm management as a strategic product because (1) it addressed the risk (marginally) of being a single product company, (2) it increased (marginally) the Company’s addressable market, (3) it represented a growth opportunity given iRhythm’s low MCT market share, and (4) it received about 4x the reimbursement of the Zio XT/Monitor.", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-0395-748f-9565-d1bebd13e441", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.1, "x": 0.45, "y": 0.54 }, "kind": "image", "text": "≠", "attrs": null, "subkind": "illustration", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "744fce85-ffa8-4334-b4d9-a05fb4985402", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.09, "w": 0.96, "x": 0.02, "y": 0.83 }, "kind": "paragraph", "text": "'...based on your marketing materials, website, and other documentation, the Zio AT System is intended for “near real-time monitoring” and “high-risk patients,” even though the Zio AT System is not cleared for these indications. When used in this patient population, the Zio AT System may cause or contribute to serious injury or death because life-threatening arrhythmias may not receive timely treatment.' - Excerpt from FDA Warning Letter", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "5fec4080-1b76-4306-ae1b-018fbe3ca2c0", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.11, "w": 0.96, "x": 0.02, "y": 0.17 }, "kind": "paragraph", "text": "The Zio AT has long been promoted by iRhythm management as a strategic product because (1) it addressed the risk (marginally) of being a single product company, (2) it increased (marginally) the Company's addressable market, (3) it represented a growth opportunity given iRhythm's low MCT market share, and (4) it received about 4x the reimbursement of the Zio XT/Monitor. However, the record of events should now force investors to re-examine everything they've been told about the product.", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "66819ad0-167c-4d67-9ab1-07664a2820b1", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“We have a perfect product to address putting information into the hands of the patient on a near real-time basis. We checked that box incredibly well.” — iRhythm CEO Blackford at Investor Day, 9/21/22; “It's not quite competitive to the degree that we would like it to be.” — iRhythm CEO Blackford at J.P. Morgan Conference, 1/13/25; “...I also have a very, very strong point of view that it's just not quite the right product for the market...” — iRhythm CEO Blackford on Q3 2024 Earnings Call, 10/30/24; “...based on your marketing materials, website, and other documentation, the Zio AT System is intended for “near real-time monitoring” and “high-risk patients,” even though the Zio AT System is not cleared for these indications. When used in this patient population, the Zio AT System may cause or contribute to serious injury or death because life-threatening arrhythmias may not receive timely treatment.” — Excerpt from FDA Warning Letter", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-0395-748f-9565-d63a72679e4a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.7, "x": 0.02, "y": 0.965 }, "kind": "source-note", "text": "Source: Bloomberg, iRhythm Q3 2024 earnings call transcript, FDA Warning Letter dated 5/25/23 (CMS# 643474), Spruce Point research", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "88a36509-baba-473c-94dc-db1564864ca6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.52, "w": 0.96, "x": 0.02, "y": 0.3 }, "kind": "table", "text": "The Blackford Pitch vs Reality", "attrs": null, "subkind": "data", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "4c795ac1-8398-4ed4-b5c3-f9b5f6468bf5", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.65, "x": 0.31, "y": 0.03 }, "kind": "title", "text": "The Zio AT Has Long Been Considered A Strategic Product For iRhythm", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "296b6f6e-7f00-4842-a8c9-2b452e7b6c6a", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [ { "name": "ceo-quote-contradiction", "slug": null, "matchId": "a0210795-fd9e-4190-ba37-9c84dd658a50", "evidence": "Contrasts CEO statements from 2022/2023 with 2024/2025 statements to expose a shift in narrative.", "confidence": 0.95 } ], "arcBeats": [ { "to": 24, "from": 8, "beatId": "98bf75b1-d631-41a2-8007-79b7391e3925", "arcName": "Overcoming the Monster", "arcSlug": "overcoming-monster", "beatName": "Expose Contradiction", "beatSlug": null, "evidence": "The document presents various contradictions and concerns regarding iRhythm's products and practices.", "position": 1, "confidence": 0.8, "parentBeatName": null, "parentBeatSlug": null } ], "loops": [ { "to": 20, "from": 9, "name": "The Reveal", "slug": "05-the-reveal", "bestFor": "Product launches, strategic pivots, unexpected findings", "matchId": "8bdc237c-9f95-46ed-95d1-4a4201a5a71e", "evidence": "The document presents various concerns and criticisms of iRhythm.", "position": 0, "objective": "To reveal concerns about iRhythm's products and management practices", "structure": "Setup the Question -> Build Suspense -> The Big Reveal", "confidence": 0.7, "description": "Build mystery and anticipation, then deliver a surprising or powerful conclusion" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }